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Abstract—Background: Ataxia with oculomotor apraxia type 2 (AOA2) is characterized by onset between age 10 and 22
years, cerebellar atrophy, peripheral neuropathy, oculomotor apraxia (OMA), and elevated serum alpha-fetoprotein (AFP)
levels. Recessive mutations in SETX have been described in AOA2 patients. Objective: To describe the clinical features of
AOA2 and to identify the SETX mutations in 10 patients from four Italian families. Methods: The patients underwent
clinical examination, routine laboratory tests, nerve conduction studies, sural nerve biopsy, and brain MRI. All were
screened for SETX mutations. Results: All the patients had cerebellar features, including limb and truncal ataxia, and
slurred speech. OMA was observed in two patients, extrapyramidal symptoms in two, and mental impairment in three.
High serum AFP levels, motor and sensory axonal neuropathy, and marked cerebellar atrophy on MRI were detected in all
the patients who underwent these examinations. Sural nerve biopsy revealed a severe depletion of large myelinated fibers
in one patient, and both large and small myelinated fibers in another. Postmortem findings are also reported in one of the
patients. Four different homozygous SETX mutations were found (a large-scale deletion, a missense change, a single-base
deletion, and a splice-site mutation). Conclusions: The clinical phenotype of oculomotor apraxia type 2 is fairly homoge-
neous, showing only subtle intrafamilial variability. OMA is an inconstant finding. The identification of new mutations
expands the array of SETX variants, and the finding of a missense change outside the helicase domain suggests the
existence of at least one more functional region in the N-terminus of senataxin.
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Ataxia with oculomotor apraxia type 2 (AOA2,
OMIM 606002) was first described in a Japanese1
and a Pakistani family.2 Reported clinical features
include onset between the ages of 10 and 22 years,
elevated serum alpha-fetoprotein (AFP) levels, pe-
ripheral neuropathy, and cerebellar atrophy on
MRI.3 Subtle cognitive changes, consistent with exec-
utive dysfunction, have previously been reported,3
but mental retardation or dementia have not. Other
clinical features include extrapyramidal signs (chore-
iform movements, dystonia, and tremor) and ele-
vated serum creatine kinase (CK) levels.
Neuropathologic features of AOA2 have not been re-
ported. Recessive mutations in SETX on chromo-
some 9q34 have been found in AOA2.4 Dominant
mutations in the same gene occur in a form of juve-
nile amyotrophic sclerosis (ALS4).5 SETX encodes
senataxin, a 2677-amino acid protein of still un-
known function.4
We report the clinical and molecular findings in
10 patients from four Italian AOA2 families carrying
novel SETX mutations, and postmortem brain exam-
ination of one of these patients.
Methods. Clinical study. The pedigrees of the four families are
shown in figure 1. Families 1 and 2 were from southern Italy,
Family 3 from central Italy, and Family 4 from a mountain region
in northern Italy populated by the descendants of a small number
of German settlers who have inhabited these isolated Alpine val-
leys for generations. The patients of Families 1 and 2 were from a
group of 35 selected patients with recessive or sporadic progres-
sive ataxia and peripheral neuropathy. They were screened for
SETX mutations in exon 10. The members of Families 3 and 4
were referred by L.C. from the Italian ataxia-telangiectasia (AT)
registry, and had normal levels of ATM protein. They were
screened for all SETX exons.
Detailed medical histories were obtained, and all 10 patients
underwent complete neurologic examinations and routine labora-
tory tests, including vitamin E and serum CK. Serum AFP was
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measured in six patients. Eight patients underwent brain MRI.
Peripheral nerve conduction studies were carried out in eight
patients, and sural nerve biopsies in two. A postmortem examina-
tion was performed in Patient 11.
Molecular study. After written informed consent was ob-
tained from all the patients, genomic DNA was extracted from
peripheral blood. The coding sequence and the intron-exon junc-
tions of SETX (GenBank accession number: NM_015046.4) were
amplified by PCR using primers listed in table E-1 (on the Neurol-
ogy Web site at www.neurology.org). PCR-amplified products were
agarose gel-purified, and directly sequenced. A duplex PCR using
primer pairs encompassing exons 15–24 and 16–17 was designed
to search for the large-scale deletion in Family 3. A PCR-RFLP
strategy, employing RsaI, was adopted to assess the segregation of
the mutation in Family 4 (table E-2). To verify the effects of the
deletion and the donor splice-site mutations, an RT-PCR was car-
ried out on polyA! RNA purified from skin fibroblasts (Patient 4)
or immortalized lymphoblastoid cell lines (Patient 9) using the 1st
Strand cDNA Synthesis Kit (Roche, Germany).
Results. Clinical features. The clinical findings are
summarized in the table. The mean age at disease onset "
SD was 20.3 " 8.1 year (range 3 to 30). The initial symp-
tom was gait ataxia in all cases. Although the disease
progression was generally slow, no patient was able to
walk independently at the time of evaluation. Mean time
to wheelchair " SD was 15.8 " 7.4 years. All the patients
had cerebellar features, including limb and truncal ataxia,
and slurred speech. Gaze nystagmus was present in eight
subjects. Oculomotor apraxia (OMA)—or rather, eye-head
dissociation during voluntary lateral head movements—
was present in two patients. The presence and the severity
of this feature varied in different clinical examinations. All
the patients presented swallowing difficulties, clinical and
neurophysiologic features suggesting peripheral neuropa-
thy, and skeletal and foot deformities. Vibration and posi-
tion senses were impaired in all but one. Three patients
presented mild mental decline (onset at around age 50
years), but formal neuropsychological tests were not per-
formed. Extrapyramidal symptoms, including choreiform
head movements and truncal dystonia in one patient, and
Figure 1. Pedigree of the Italian families with AOA2.
Table Clinical and molecular features of AOA2 Italian patients
Family 1 2 3 3 4 4 4 4 4 4
Patient 1 2 3 4 5 6 7 8 9 10
Parental consanguinity
Sex/age at onset, y/age at
examination, y
Duration until wheelchair, y
Sign at onset
Gait ataxia
Dysarthria
Nystagmus
Dysphagia
Ocular motor apraxia
Areflexia
LL weakness
UL-LL distal wasting
Impaired position/
vibration sense
Cognitive decline
Skeletal deformities
Foot deformity
Cerebellar atrophy at MRI
Axonal neuropathy
Increased serum AFP levels
Homozygous SETX
mutation
Mutation effects
No
F/15/27
17
CA
!!
!
!
!
!
!!
!
!
!
–
!
!
!
!
!
3466delG
fs1157X
Yes
M/3/32
21
CA
!!
!
!
!
!
!!
!
!!
!
?
!
!
!
!
!
1406A#G
H469R
Yes
M/15/40
17
CA
!!
!
!
!
–
!!
!
!!
!
–
!
!
!
!
!
c.6106!3393_
c.7101–22
del20648bp/
ins 25bp
Eight exons
deleted
Yes
F/19/38
17
CA
!!
!
!
!
–
!!
!
!!
!
–
!
!
!
!
!
c.6106!3393_
c.7101–22
del20648bp/
ins25bp
Eight exons
deleted
Possible
F/25/67
28
CA
!!
!
!
!
–
!!
!!
!!
!
!
!
!
NP
NP
NP
c.7199!5G#A
Exon 25
skipped
Possible
M/18/66
15
CA
!!
!
!
!
–
!!
!!
!!
!
!
!
!
NP
NP
NP
c.7199!5G#A
Exon 25
skipped
Possible
M/30/54
5
CA
!!
!
!
!
–
!!
!!
!!
!
!
!
!
!
!
NP
c.7199!5G#A
Exon 25
skipped
Possible
F/30/58
5
CA
!!
!
–
!
–
!!
!!
!!
!
–
!
!
!
!
NP
c.7199!5G#A
Exon 25
skipped
Yes
F/25/60
23
CA
!!
!
–
!
–
!!
!!
!!
!
–
!
!
!
!
!
c.7199!5G#A
Exon 25
skipped
Yes
M/23/49
10
CA
!!
!
!
!
–
!!
!!
!!
!
–
!
!
!
!
!
c.7199!5G#A
Exon 25
skipped
See text for mutations details. Numbering of the mutation refers to the first ATG codon of the mRNA as nucleotide !1–3. Presence and severity of features: ! $ mild
to moderate; !! $ severe; – $ absent.
NP $ not performed; LL $ lower limbs; UL $ upper limbs; AFP $ alpha-fetoprotein; CA $ cerebellar ataxia.
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head tremor in another, rapidly disappeared as the disease
progressed. Routine laboratory findings, including serum
CK, cholesterolemia, albuminemia, and vitamin E levels,
were normal. Raised serum AFP levels, motor and sensory
axonal neuropathy, and marked cerebellar atrophy on
brain MRI were detected in all the patients, who under-
went these examinations. Sural nerve biopsy revealed a
severe loss of large myelinated fibers in Patient 1 (figure
2D), and both small and large myelinated fibers in Patient
2.
Pathologic findings. Postmortem brain examination
was performed in Patient 11, who died of heart failure at
age 79 years. The overall size of the brain, which weighed
only 850 g after fixation, appeared considerably reduced.
All brain structures appeared small; in particular, we ob-
served atrophy of the cerebellar folia, and a marked widen-
ing of the sulci. The cerebellar atrophy was most evident at
the level of the vermis and the anterior lobe (figure 2A).
The brainstem and spinal cord were slightly reduced in
size, but otherwise unremarkable. The substantia nigra
appeared normally pigmented. Atheromatous plaques
were present in all the arteries of the circle of Willis.
Histologically, the cortical neurons were normal in both
number and shape. The cerebellar cortex showed a marked
loss of Purkinje cells, and mild fibrous gliosis, which was
more severe in the vermis than in the hemispheres (figure
2B). Neither inclusion bodies nor torpedoes were found.
The neurons of the dentate nuclei were slightly reduced in
number. Chromatolysis of the oculomotor and raphe nuclei
was observed in the brainstem. The inferior and accessory
olives appeared relatively spared. Severe demyelination of
the gracilis and cuneatus funiculi, and degeneration of the
Clarke’s columns with gliosis, were observed in the spinal
cord (figure 2C).
Molecular analyses. We identified four new mutations
in SETX (figure 3). In Family 1, a homozygous single-base
deletion, c.3466delG, was identified, predictively producing
a frameshift after amino acid residue 1155 with a prema-
ture stop codon at 1157 (fs1157X). In Family 2, a homozy-
gous c.1406A#G mutation was found, resulting in the
substitution of arginine for histidine at residue 469
(H469R). This substitution was not found in 200 Italian
control chromosomes. In Family 3, we identified a homozy-
gous large-scale rearrangement about 20 kb in size (c.6106
! 3393_c.7101-22del20648bp/ins25bp). The mutation de-
leted the sequences of exons 16–23, and was flanked by an
8-bp tandem repeat (5=-GTAAATTT-3=). In cultured skin
fibroblasts, the large-scale rearrangement produced two
alternative transcripts (figure E-1b), both predictively re-
sulting in premature protein truncation at residue 2040. In
Family 4, we detected a homozygous c.7199 ! 5G#A mu-
tation in the conserved donor splice site of intron 25. Anal-
ysis of the cDNA from lymphoblastoid cells showed that
the splice-site mutation caused skipping of exon 25 (figure
E-1d) and a predicted protein cropped of 10% of its
C-terminus sequence. Cosegregation between the different
mutations and the disease was confirmed in Families 3
(figure E-1a) and 4 (figure E-1c) but could not be verified in
Family 2 because the patient’s relatives were not available
for testing.
Discussion. Autosomal recessive cerebellar atax-
ias (ARCAs) are heterogeneous diseases. It is now
possible to identify a group of ARCAs with confirmed
or highly likely DNA repair defects.6 As regards the
neurologic phenotype, these diseases are commonly
characterized by progressive ataxia and peripheral
neuropathy, usually associated with OMA.7 Two ma-
jor subgroups can be identified according to impair-
ment of double and single strand repair. AT and
AT-like disorder both fall into the first category, inFigure 3. Localization of the four new mutations in SETX.
Figure 2. (A–C) Pathology findings in
Patient 11. (A) Cerebellar atrophy ap-
pears more evident at vermis and ante-
rior lobe level. (B) Marked loss of
Purkinje cells. (C) Demyelination of
gracilis and cuneate funiculi. (D) Nerve
biopsy of Patient 2 showing severe loss
of large myelinated fibers.
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which chromosomal instability, sensitivity to ioniz-
ing radiations, and susceptibility to cancer (AT) are
associated features.8-10 The second category includes
ataxia with oculomotor apraxia type 1 (AOA1),
spinocerebellar ataxia with neuropathy 1 (SCAN1),
and possibly AOA2.4,11-14 AOA2 shares several clini-
cal features with AOA1, including gait ataxia, cere-
bellar atrophy, and sensorimotor neuropathy, but
can be distinguished by a later age at onset, the
presence of high or mildly elevated serum AFP lev-
els, and a better functional prognosis. Additional
clinical features such as OMA and choreoathetosis
are less common.
This report describes a series of Italian AOA2 pa-
tients with proven genetic defects in SETX. Only two
such series have been reported to date: one included
six families from different Mediterranean areas and
from the West Indies, in which the disease was
linked to the 9q34 locus3; the other was a single
cluster of 10 French-Canadian families with ataxia
and neuropathy (known as the Quebec cluster).15
Mean age at onset in our series was slightly higher
than in these studies (20.3 years vs 15.1 and 14.8
years).3,15 Although it is included in the acronym,
OMA is not mandatory in AOA23,15: it was found in
20% of our patients, in 56% of the multiethnic co-
hort,3 and in none of the Quebec cluster.15 Whereas
three of the Italian patients presented cognitive im-
pairment, and executive dysfunction was described
in the multiethnic study,3 the French-Canadian pa-
tients had normal intelligence.15 Similarly, extrapy-
ramidal features do not appear to be constant in
AOA2: only one patient in our study presented cho-
reic or dystonic movements—which later disap-
peared—whereas about 40% of the patients in the
multiethnic study3 had persistent chorea throughout
the course of the disease. Conversely, none of the
Quebec patients presented movement disorders. As
in previous studies, we observed a fairly homoge-
neous inter- and intrafamilial phenotype. The pat-
tern of disease progression varied in Family 4:
Patients 7 and 8 were confined to a wheelchair 5
years after disease onset, whereas the progression
was slower in the other family members (range 10 to
28 years). Unlike AT, AOA2 does not seem to be
associated with an increased susceptibility to cancer,
although two of the French-Canadian patients died
of cancer.15
Taken together, the pathologic data reported here
in one Italian patient, and the clinical presentation
described both in this new series and in the previous
AOA2 families,3,15 suggest that senataxin plays a
crucial role in cerebellar, anterior horn, and dorsal
root neuron survival. In addition, the fact that two
patients in our study entered menopause in early
adulthood, and that early-onset menopause was also
reported in the previous multiethnic study,3 suggests
that senataxin might also be involved in germ line
cell survival. However, the function of senataxin is
poorly understood. Truncations (observed in Fami-
lies 1, 3, and 4) and missense changes (Family 2)
result in a similar phenotype, suggesting that both
mutations cause disease through a loss-of-function
mechanism. Senataxin’s carboxy-terminus shares
similarities with the superfamily 1 of helicases. The
missense H469R identified in Family 2 falls outside
this domain, and thus raises the possibility that
there is at least one other regulatory region in the
N-terminus of senataxin. Given the extensive homol-
ogies with the fungal Sen1p proteins,4 which have
RNA and DNA helicase activity, and are involved in
splicing and termination of tRNA and small nuclear
RNA, the possible role of senataxin in the spliceo-
some machinery warrants further investigation.16
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